Introduction: Despite the acceptance of concomitant chemoradiation (CRT) as an alternative to total laryngectomy (TL) in locally advanced laryngeal cancer (LALC), laryngeal preservation is sparingly recommended in developing countries. We report on prognostic factors and survival in T3/T4 laryngeal cancer treated with concomitant CRT at Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH and RC) to provide comparison with other geographic locations.
INTRODUCTION
Worldwide estimates predict over 160,000 new cases of laryngeal cancer in males and 22,000 cases among females. These predictions account for 1.7% of all new cancer cases around the world. Men are more commonly affected than females. The male/female ratio of almost 7:1 in laryngeal cancer is higher than for cancer at any other site. 1 Pakistan falls into a high risk head and neck cancer geographical zone. Data from the population-based cancer registry in Karachi shows head and neck malignancies to account for approximately 21% of the cancers in males and about 11% in females. The age standardized incidence rate of 8.6 per 100,000 in Karachi for laryngeal cancer is among the highest in Asia and it constitutes 5.0% of all cancers in men. 2 Over 95% of laryngeal cancers are of squamous cell histology and the relationship with cigarette smoking is well established. 3 Carcinoma of the vocal cords is the most common form of laryngeal cancer followed by supraglottic cancer. Subglottic carcinomas are rare and account for less than 2% of all laryngeal cancers. 4 Early laryngeal cancer has a high cure rate with either radiation or voice preserving modern surgical techniques. 5 The treatment of locally advanced disease has gradually evolved from radical surgery as the mainstay to larynx preserving therapies as the principle treatment. The treatment strategies available to preserve the larynx include conservative laryngeal surgery, radiation alone, induction chemotherapy followed by radiation and concomitant chemoradiation (CRT). 6 Laryngeal preservation is sparingly recommended in developing countries and total laryngectomy (TL) continues as the most widely practiced treatment in locally advanced disease. We report on prognostic factors and survival in locally advanced laryngeal cancer treated with concomitant CRT at Shaukat Khanum Memorial Cancer Hospital and Research Center (SKMCH & RC) to provide comparison with other geographic locations. 
PATIENTS AND METHODS

Our
Assessment of Response
Response to concomitant CRT was assessed during 6-8 weeks after the completion of therapy by examination of the head and neck and fiberoptic nasendoscopy. Complete response was defined as disappearance of all disease. Thereafter, patients were followed up at 3 monthly intervals. Patients with suspected persistent or recurrent disease were restaged with MRI neck and biopsy.
Statistical Analysis
Statistical Package for Social Sciences, version 10, was used to run statistical analysis. Survival analyses were carried out through univariate and multivariate methods. The former was primarily used to screen through the potential prognostic factors searching for any, that was significantly related to survival. The log rank test was used to measure the significance. Cox Proportional Hazards Model was applied to test if the variables significantly associated with survival in the Kaplan Meier analysis were also significantly associated with the variables in the multivariate survival analysis by determining the probability of end point called the hazard. Probability of entry into the model was set at 0.10 and of removal at 0.20 and backward logistic regression method was constructed to see which variables were significantly associated with survival. The level of significance for the factors analysed with the multivariate survival analysis were calculated by the likelihood ratio test. For overall survival (OS) and laryngectomy free survival (LFS), the duration was calculated from the date of start of treatment to the time of event. Patients terminally ill at last follow-up are considered dead. Deaths and losses to followup were considered as events for overall OS and LFS. All patients not obtaining a complete response in 6-8 weeks following completion of CRT represent events for LFS. Data was evaluated in March 2010.
RESULTS
Patient characteristics are shown in Table 2 . Patients with T4 tumors (Fig. 3) , positive neck nodal disease (Fig. 4) , supraglottic site ( 
DISCUSSION
The current treatment trend in advanced laryngeal cancer is towards the avoidance of radical surgery whenever possible. Induction chemotherapy followed by radiotherapy as organ preserving treatment gained acceptance in 1990s following Veterans Affairs Laryngeal Cancer Study Group trial. The larynx was preserved in 64 percent in the nonsurgical arm, retained in approximately half of the long-term survivors in the CRT arm. 8 The Radiation Therapy Oncology Group and the Head and Neck Inter. Group conducted a randomized trial (RTOG 91-11) to investigate the contributions of chemotherapy and radiotherapy to larynx-preserving treatment. The three arm study compared induction chemotherapy followed by radiotherapy, concurrent CRT and the two-year survival rate was 68 percent in both groups. 7 The ability to preserve the larynx without compromising survival established the use of induction chemotherapy followed by radiotherapy as a nonsurgical option for patients with advanced laryngeal cancer. In the European Organization for Research and Treatment of Cancer (EORTC) Hypopharynx Trial, functional larynx was with and radiotherapy alone. The primary objective of the trial was to compare the rates of laryngeal preservation associated with three treatments. Patients with T1 disease or high-volume T4 disease (defined as more than 1 cm of invasion of the base of the tongue or tumor penetration of thyroid cartilage into soft tissues) were excluded. In two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88%) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75%, P = 0.005) or radiotherapy alone (70%, P < 0.001). Grade 3 to 4 mucosal toxicity was twice as frequent with concurrent treatment as with other two arms. There was no difference in late toxicity among the three arms. On the basis of these findings, radiotherapy with concomitant administration of cisplatin emerged as the new standard for CRT treatment.
9
A meta-analysis of induction chemotherapy and definite radiation trials in laryngeal preservation showed a laryngeal preservation rate among survivors to be 58% and that survival was not compromised by function sparing approach. It was unclear whether induction chemotherapy had an independent therapeutic effect or allowed for the selection of patients suitable for laryngeal preservation with radiation. 10 Gemcitabine and cisplatin are both drugs with proven clinical activity in a variety of solid tumors, have no overlapping toxic side-effects and are different with respect to cellular metabolism. In combination with cisplatin, the regime has a documented favorable toxicity profile in randomized trials for lung and bladder cancer. 11, 12 The standard CF regime yields a 15-30% overall response rate and 4-6 month survival in advanced or recurrent head and neck cancer. 13, 14 In the EORTC trial for patients with advanced head and neck cancer, single agent gemcitabine produced a 13% response rate with mild toxicity. 15 In combination with cisplatin, a 23% overall response rate was observed in advanced or recurrent head and neck cancer. 16 In our institution, GC combination is used in untreated locally advanced head and neck cancer patients as an ambulatory outpatient schedule due to its low toxicity and comparable response rates. In our series induction, chemotherapy was predominantly used in patients with more advanced disease. While there was no significant difference in survival among patients treated with or without induction, chemotherapy, the group treated without chemotherapy had a relatively improved outcome. This observation is likely due to lower stage disease treated with no induction chemotherapy.
There are no reliable predictors of outcomes for larynx preservation treatment. However, patients with extensive cartilage invasion, tongue base involvement, compromised airways and supraglottic subsite are considered poor candidates for a function sparing approach. 9, 17 The LFS for the whole group at 5 years in our series was 47%. These results are marginally inferior to laryngeal preservation rates of CRT treatment arms of large randomized trials. [7] [8] [9] The lower LFS in this series is likely to be due to a higher proportion of high risk patients treated with CRT. Over 20% of the patients had supraglottic subsite and 60% had T4 disease. The 5 year LFS for supraglottic and glottic carcinomas was 29% and 65% respectively (p = 0.001). On univariate analysis, the survival of these patients was significantly inferior to T3 tumors (56% vs 42%, p = 0.04). Several studies have shown poor outcome of patients with tracheotomy. 18 The dismal survival of patients with tracheotomy in this series is consistent with literature and tracheotomy emerged as the only independent prognostic factor significantly associated with poor LFS on multivariate analysis. The potential risk of prolongation of radiotherapy treatment time in head and neck is well documented. 19 Prolonged overall radiotherapy treatment time has a major effect on locoregional control and survival. In this series, overall treatment time showed a trend towards improved LFS survival with radiotherapy treatment > 50 days was 43% in contrast to 54% in patients with radiotherapy treatment time of < 50 days. Treatment related toxicity accounted for unscheduled radiation treatment interruption in only a few cases. In the majority of patients, gaps in radiation treatment were not related to treatment toxicity. Patients undergoing treatment at SKMCH & RC travel from all over the country involved long road and rail journeys. Family commitments, commuting, extreme weather and machine breakdown are some of the factors causing prolonged radiotherapy treatment time in this region.
Salvage among local failures in our series was disappointing. The unsatisfactory salvage rates can be attributed either to advanced locoregional disease or treatment biased by patients leading to refusal of curative surgery. There is no data in developing countries on refusal rate for total laryngectomy but the number is likely to be high due to illiteracy and and low levels of health awareness. Patients often seek traditional or alternative therapies over surgical treatment that inevitably leads to delay and progression rendering initially operable disease inoperable.
Laryngectomy is among the most mutilating and feared treatments of cancer. The loss of voice, altered swallowing, and a permanent tracheotomy, continue to affect the patients' quality of life (QOL), both in terms of physical and psychological status. [20] [21] [22] In developed countries, most patients undergo voice rehabilitation following laryngectomy however, a significant proportion are disappointed with results of voice restoration. 23 Improved voice rehabilitation following TL in particular with tracheoesophageal (TE) voice restoration has changed the situation as it provides a good functional outcome and better QOL. 24 The availability of voice restoration options in developing countries is limited and remains inaccessible for larger population. The average family annual income in South Asia is less than the retail price of a good artificial larynx; and the cost of TE puncture prostheses makes voice restoration with these devices unfeasible for the overwhelming majority of cases. The morbidity of TL is compounded in these countries where loss of speech in a predominantly illiterate patient population who are unable to write has an even more devastating impact on their QOL. The likelihood of laryngectomies being forced into an isolated life as a mute and dysphasic recluse may explain the observed high refusal rate for laryngectomy in our population. 24 In summary, our survival rates for locally advanced laryngeal cancer treated with concomitant CRT are acceptable and discussion on laryngeal preservation should form a part of the consultative process in developing countries. In patients requiring tracheotomy for compromised airways, our study supports the use of TL as outcome with CRT is poor. The high refusal rate for both primary and salvage TL is of concern; there is need to expand voice rehabilitation, counselling and support services in the developing world to increase acceptance of TL as a therapeutic procedure.
